A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Verdinexor (Primary)
  • Indications Viral infections
  • Focus Adverse reactions
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 21 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
    • 24 Sep 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov.
    • 15 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top